You just read:

FDA Approves Eisai's LENVIMA™ (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer

News provided by

Eisai Inc.

Feb 13, 2015, 03:55 ET